Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

Add ONVO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 12/17/2017 12:45:18 AM - Followers: 313 - Board type: Free - Posts Today: 0


     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.


ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014

IR and Media Contacts:
Investor Relations Contact:
Media Contact:

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994

For all the latest company information, details, news, please visit

Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:


Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.


World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  


NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods. (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO News: Statement of Changes in Beneficial Ownership (4) 12/04/2017 09:01:36 AM
ONVO News: Current Report Filing (8-k) 12/01/2017 06:08:56 AM
ONVO News: Report: Developing Opportunities within Social Reality, The Finish Line, Facebook, Organovo, Plug Power, and Intrexon — Fut... 11/27/2017 08:20:00 AM
ONVO News: Current Report Filing (8-k) 11/09/2017 04:12:01 PM
ONVO News: Quarterly Report (10-q) 11/09/2017 04:11:06 PM
#10088   Thank you bettyfordallstar 12/17/17 12:45:18 AM
#10087   RE that large end of day trade: rongreen 12/16/17 11:31:25 PM
#10086   Thank you. Let's see a few more of those bettyfordallstar 12/16/17 11:02:22 PM
#10085   According to IH, there was a 2,313,083 share Alvie 12/16/17 09:58:26 PM
#10084   Does anyone have L2 ? There was a bettyfordallstar 12/15/17 08:26:47 PM
#10083   The FDA has reviewed more than 100 devices RandolRocketman 12/10/17 10:51:12 AM
#10082   The FDA has reviewed more than 100 devices RandolRocketman 12/10/17 10:51:10 AM
#10081   Did hear the ceo In conference call say bettyfordallstar 12/07/17 06:47:53 PM
#10080   I really bet you want to load up bettyfordallstar 12/07/17 06:45:04 PM
#10079   Looks like the former CEO still has a RandolRocketman 12/04/17 11:29:33 AM
#10078   I'm thinking more like Robocop. RandolRocketman 12/01/17 08:53:05 PM
#10077   I love this train of thought. Thanks for posting. rongreen 12/01/17 05:37:33 PM
#10076   Just what I thought of when I read 80857 12/01/17 04:51:08 PM
#10075   However long before that happens, I can see RandolRocketman 12/01/17 01:52:08 PM
#10074   Or terminator 80857 11/30/17 12:09:15 PM
#10073   Thats a great thought.. Bladerunner comes to mind TheMoneyTree 11/29/17 06:55:54 PM
#10072   I think many of us here share that perspective. morley480 11/29/17 01:42:02 PM
#10071   Interesting perspective. accrypto1 11/29/17 12:59:08 PM
#10070   I think smart money got into ONVO early RandolRocketman 11/28/17 11:57:18 PM
#10069   That's entirely possible. Still I think, with RandolRocketman 11/27/17 09:31:24 AM
#10068   Sure dump all your shares for fifty cents CIMA7 11/26/17 03:58:09 AM
#10067   Interesting end of the day spike bettyfordallstar 11/24/17 05:06:55 PM
#10066   More than likely it will be later.they will bettyfordallstar 11/23/17 04:15:01 AM
#10065   I know right? More likely Organovo will move RandolRocketman 11/23/17 01:06:53 AM
#10064   long here @ 1.45 chris hedges 11/22/17 04:00:00 PM
#10063   Dip and rip this morning? Still believe ONVO RandolRocketman 11/10/17 09:56:49 AM
#10062   Well, thoughts anyone? The one good thing bettyfordallstar 11/09/17 05:52:37 PM
#10061   Organovo Announces Fiscal Second-Quarter 2018 Results; Company Shifts BuckeyeStocks 11/09/17 04:14:22 PM
#10060   SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- RandolRocketman 11/06/17 10:51:17 AM
#10059   can somebody else lend a hand chris hedges 10/30/17 02:12:21 PM
#10058   BASF signs 3D bioprinting cosmetics deal with Poietis Frenchy2016 10/27/17 10:32:54 AM
#10057   I am in since some months. Meanwhile I Aston Martin 10/25/17 06:32:38 AM
#10056   The volume is definitely saying something is up. RandolRocketman 10/23/17 01:52:08 PM
#10055   I just took notice of this stock. Sounds drlord10 10/23/17 08:40:07 AM
#10054   Only unrealized gain and unrealized loss but still bigideaportugal 10/21/17 08:10:45 AM
#10053   Greed never wins, my friend.. Rode this to CaptHowdy 10/21/17 07:23:40 AM
#10052   * * $ONVO Video Chart 10-20-17 * * ClayTrader 10/20/17 05:10:54 PM
#10051   UnFREAKINbelievable!!! Been in this CHIT since 2013 $1.99 bigideaportugal 10/12/17 03:08:09 PM
#10050   Holy moly, under a buck and a half! RandolRocketman 10/12/17 02:18:34 PM
#10049   Better yet, get the subsidies that he does. flick 10/11/17 02:31:16 PM
#10048   Agreed with everything except your event horizon. I RandolRocketman 10/11/17 10:10:30 AM
#10047   Thanks. Makes sense. I agree with morley480 10/11/17 09:59:54 AM
#10046   some funds have rules on minimum price, and Northrock 10/10/17 05:57:54 PM
#10045   * * $ONVO Video Chart 10-10-17 * * ClayTrader 10/10/17 05:12:24 PM
#10044   With volume too. What do you suppose morley480 10/10/17 04:25:29 PM
#10043   Considerable dip here today. May be a RandolRocketman 10/10/17 03:56:52 PM
#10042   Organovo Announces Preliminary Fiscal Second-Quarter Total Revenue; Company Alvie 10/04/17 06:00:58 PM
#10041   The Competitive Case For Organovo Holdings $ONVO BuckeyeStocks 09/20/17 09:12:00 AM
#10040   ..getting interesting again! From a weak sub 2 ddbl_our_buck 08/31/17 04:26:55 PM
#10039   Organovo Sponsors Pioneering Research With Amgen and Medikine RandolRocketman 08/23/17 01:05:59 PM